PLIN1 Haploinsufficiency Is Not Associated With Lipodystrophy

Thomas W. Laver, Kashyap A. Patel, Kevin Colclough, Jacqueline Curran, Jane Dale, Nikki Davis, David B. Savage, Sarah E. Flanagan, Sian Ellard, Andrew T. Hattersley, Michael N. Weedon

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Context: Monogenic partial lipodystrophy is a genetically heterogeneous disease where only variants with specific genetic mechanisms are causative. Three heterozygous protein extending frameshift variants in PLIN1 have been reported to cause a phenotype of partial lipodystrophy and insulin resistance.

Objective: We investigated if null variants in PLIN1 cause lipodystrophy.

Methods: As part of a targeted sequencing panel test, we sequenced PLIN1 in 2208 individuals. We also investigated the frequency of PLIN1 variants in the gnomAD database, and the type 2 diabetes knowledge portal.

Results: We identified 6/2208 (1 in 368) individuals with a PLIN1 null variant. None of these individuals had clinical or biochemical evidence of overt lipodystrophy. Additionally, 14/17,000 (1 in 1214) individuals with PLIN1 null variants in the type 2 diabetes knowledge portal showed no association with biomarkers of lipodystrophy. PLIN1 null variants occur too frequently in gnomAD (126/138,632; 1 in 1100) to be a cause of rare overt monogenic partial lipodystrophy.

Conclusions: Our study suggests that heterozygous variants that are predicted to result in PLIN1 haploinsufficiency are not a cause of familial partial lipodystrophy and should not be reported as disease-causing variants by diagnostic genetic testing laboratories. This finding is in keeping with other known monogenic causes of lipodystrophy, such as PPARG and LMNA, where only variants with specific genetic mechanisms cause lipodystrophy.

Original languageEnglish
Pages (from-to)3225-3230
Number of pages6
JournalJournal of Clinical Endocrinology & Metabolism
Volume103
Issue number9
DOIs
Publication statusPublished - Sep 2018
Externally publishedYes

Cite this

Laver, T. W., Patel, K. A., Colclough, K., Curran, J., Dale, J., Davis, N., ... Weedon, M. N. (2018). PLIN1 Haploinsufficiency Is Not Associated With Lipodystrophy. Journal of Clinical Endocrinology & Metabolism, 103(9), 3225-3230. https://doi.org/10.1210/jc.2017-02662
Laver, Thomas W. ; Patel, Kashyap A. ; Colclough, Kevin ; Curran, Jacqueline ; Dale, Jane ; Davis, Nikki ; Savage, David B. ; Flanagan, Sarah E. ; Ellard, Sian ; Hattersley, Andrew T. ; Weedon, Michael N. / PLIN1 Haploinsufficiency Is Not Associated With Lipodystrophy. In: Journal of Clinical Endocrinology & Metabolism. 2018 ; Vol. 103, No. 9. pp. 3225-3230.
@article{f2aaf59078af401a80eb1efb22627671,
title = "PLIN1 Haploinsufficiency Is Not Associated With Lipodystrophy",
abstract = "Context: Monogenic partial lipodystrophy is a genetically heterogeneous disease where only variants with specific genetic mechanisms are causative. Three heterozygous protein extending frameshift variants in PLIN1 have been reported to cause a phenotype of partial lipodystrophy and insulin resistance.Objective: We investigated if null variants in PLIN1 cause lipodystrophy.Methods: As part of a targeted sequencing panel test, we sequenced PLIN1 in 2208 individuals. We also investigated the frequency of PLIN1 variants in the gnomAD database, and the type 2 diabetes knowledge portal.Results: We identified 6/2208 (1 in 368) individuals with a PLIN1 null variant. None of these individuals had clinical or biochemical evidence of overt lipodystrophy. Additionally, 14/17,000 (1 in 1214) individuals with PLIN1 null variants in the type 2 diabetes knowledge portal showed no association with biomarkers of lipodystrophy. PLIN1 null variants occur too frequently in gnomAD (126/138,632; 1 in 1100) to be a cause of rare overt monogenic partial lipodystrophy.Conclusions: Our study suggests that heterozygous variants that are predicted to result in PLIN1 haploinsufficiency are not a cause of familial partial lipodystrophy and should not be reported as disease-causing variants by diagnostic genetic testing laboratories. This finding is in keeping with other known monogenic causes of lipodystrophy, such as PPARG and LMNA, where only variants with specific genetic mechanisms cause lipodystrophy.",
keywords = "INSULIN-RESISTANCE, MUTATIONS",
author = "Laver, {Thomas W.} and Patel, {Kashyap A.} and Kevin Colclough and Jacqueline Curran and Jane Dale and Nikki Davis and Savage, {David B.} and Flanagan, {Sarah E.} and Sian Ellard and Hattersley, {Andrew T.} and Weedon, {Michael N.}",
year = "2018",
month = "9",
doi = "10.1210/jc.2017-02662",
language = "English",
volume = "103",
pages = "3225--3230",
journal = "Journal of Endocrinology & Metabolism",
issn = "0021-972X",
publisher = "ENDOCRINE SOC",
number = "9",

}

Laver, TW, Patel, KA, Colclough, K, Curran, J, Dale, J, Davis, N, Savage, DB, Flanagan, SE, Ellard, S, Hattersley, AT & Weedon, MN 2018, 'PLIN1 Haploinsufficiency Is Not Associated With Lipodystrophy' Journal of Clinical Endocrinology & Metabolism, vol. 103, no. 9, pp. 3225-3230. https://doi.org/10.1210/jc.2017-02662

PLIN1 Haploinsufficiency Is Not Associated With Lipodystrophy. / Laver, Thomas W.; Patel, Kashyap A.; Colclough, Kevin; Curran, Jacqueline; Dale, Jane; Davis, Nikki; Savage, David B.; Flanagan, Sarah E.; Ellard, Sian; Hattersley, Andrew T.; Weedon, Michael N.

In: Journal of Clinical Endocrinology & Metabolism, Vol. 103, No. 9, 09.2018, p. 3225-3230.

Research output: Contribution to journalArticle

TY - JOUR

T1 - PLIN1 Haploinsufficiency Is Not Associated With Lipodystrophy

AU - Laver, Thomas W.

AU - Patel, Kashyap A.

AU - Colclough, Kevin

AU - Curran, Jacqueline

AU - Dale, Jane

AU - Davis, Nikki

AU - Savage, David B.

AU - Flanagan, Sarah E.

AU - Ellard, Sian

AU - Hattersley, Andrew T.

AU - Weedon, Michael N.

PY - 2018/9

Y1 - 2018/9

N2 - Context: Monogenic partial lipodystrophy is a genetically heterogeneous disease where only variants with specific genetic mechanisms are causative. Three heterozygous protein extending frameshift variants in PLIN1 have been reported to cause a phenotype of partial lipodystrophy and insulin resistance.Objective: We investigated if null variants in PLIN1 cause lipodystrophy.Methods: As part of a targeted sequencing panel test, we sequenced PLIN1 in 2208 individuals. We also investigated the frequency of PLIN1 variants in the gnomAD database, and the type 2 diabetes knowledge portal.Results: We identified 6/2208 (1 in 368) individuals with a PLIN1 null variant. None of these individuals had clinical or biochemical evidence of overt lipodystrophy. Additionally, 14/17,000 (1 in 1214) individuals with PLIN1 null variants in the type 2 diabetes knowledge portal showed no association with biomarkers of lipodystrophy. PLIN1 null variants occur too frequently in gnomAD (126/138,632; 1 in 1100) to be a cause of rare overt monogenic partial lipodystrophy.Conclusions: Our study suggests that heterozygous variants that are predicted to result in PLIN1 haploinsufficiency are not a cause of familial partial lipodystrophy and should not be reported as disease-causing variants by diagnostic genetic testing laboratories. This finding is in keeping with other known monogenic causes of lipodystrophy, such as PPARG and LMNA, where only variants with specific genetic mechanisms cause lipodystrophy.

AB - Context: Monogenic partial lipodystrophy is a genetically heterogeneous disease where only variants with specific genetic mechanisms are causative. Three heterozygous protein extending frameshift variants in PLIN1 have been reported to cause a phenotype of partial lipodystrophy and insulin resistance.Objective: We investigated if null variants in PLIN1 cause lipodystrophy.Methods: As part of a targeted sequencing panel test, we sequenced PLIN1 in 2208 individuals. We also investigated the frequency of PLIN1 variants in the gnomAD database, and the type 2 diabetes knowledge portal.Results: We identified 6/2208 (1 in 368) individuals with a PLIN1 null variant. None of these individuals had clinical or biochemical evidence of overt lipodystrophy. Additionally, 14/17,000 (1 in 1214) individuals with PLIN1 null variants in the type 2 diabetes knowledge portal showed no association with biomarkers of lipodystrophy. PLIN1 null variants occur too frequently in gnomAD (126/138,632; 1 in 1100) to be a cause of rare overt monogenic partial lipodystrophy.Conclusions: Our study suggests that heterozygous variants that are predicted to result in PLIN1 haploinsufficiency are not a cause of familial partial lipodystrophy and should not be reported as disease-causing variants by diagnostic genetic testing laboratories. This finding is in keeping with other known monogenic causes of lipodystrophy, such as PPARG and LMNA, where only variants with specific genetic mechanisms cause lipodystrophy.

KW - INSULIN-RESISTANCE

KW - MUTATIONS

U2 - 10.1210/jc.2017-02662

DO - 10.1210/jc.2017-02662

M3 - Article

VL - 103

SP - 3225

EP - 3230

JO - Journal of Endocrinology & Metabolism

JF - Journal of Endocrinology & Metabolism

SN - 0021-972X

IS - 9

ER -

Laver TW, Patel KA, Colclough K, Curran J, Dale J, Davis N et al. PLIN1 Haploinsufficiency Is Not Associated With Lipodystrophy. Journal of Clinical Endocrinology & Metabolism. 2018 Sep;103(9):3225-3230. https://doi.org/10.1210/jc.2017-02662